

ONE HUNDRED EIGHTEENTH CONGRESS

Congress of the United States
House of Representatives

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115

Majority (202) 225-3641
Minority (202) 225-2927

February 22, 2023

Dr. Timothy Westlake, M.D., FFSMB., FACEP.
Emergency Department Medical Director
ProHealth Care Oconomowoc Memorial Hospital
791 Summit Avenue
Oconomowoc, WI 53066

Dear Dr. Westlake:

Thank you for appearing before the Subcommittee on Health on Wednesday, February 1, 2023, to testify at the hearing entitled "Lives Worth Living: Addressing the Fentanyl Crisis, Protecting Critical Lifelines, and Combatting Discrimination Against Those with Disabilities."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions by the close of business on Wednesday, March 8, 2023. Your responses should be mailed to Jolie Brochin, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515 and e-mailed in Word format to Jolie.Brochin@mail.house.gov.

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,



Brett Guthrie
Chair
Subcommittee on Health

cc: Anna Eshoo, Ranking Member, Subcommittee on Health

Attachment 1—Additional Questions for the Record

The Honorable Frank Pallone, Jr.

1. How will passage of the MAT Act affects efforts to treat opioid addiction in the Emergency Room? How important is it to intervene at that point of care?
2. As a doctor of Emergency Medicine, can you tell me what education on addiction you received in medical school? Residency?
3. Do you agree that more physicians, especially new physicians entering the workforce, should have access to continuing education and training to identify and treat substance use disorders?
4. What evidence is there that FRS scheduling has led to a decrease in the appearance of new FRS substances? Please give us specific numbers.
5. In response to a question from Chairman Guthrie at the January 11 roundtable, you mentioned rapid descheduling of substances that are inert and not biologically active. Do you agree that FRS found to have a lower risk or no risk to public health should be rescheduled or descheduled, respectively?